{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:53:35Z","timestamp":1789638815156,"version":"4.0.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"29","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.vaccine.2019.05.063","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:10:11Z","timestamp":1559034611000},"page":"3779-3784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Healthcare costs associated with varicella and herpes zoster in Norway"],"prefix":"10.1016","volume":"37","author":[{"given":"H\u00e5vard","family":"Haugnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmira","family":"Flem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7539-082X","authenticated-orcid":false,"given":"Torbj\u00f8rn","family":"Wisl\u00f8ff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.05.063_b0005","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12879-016-1581-4","article-title":"Varicella-zoster virus susceptibility and primary healthcare consultations in Norway","volume":"16","author":"Rimseliene","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2019.05.063_b0010","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.vaccine.2018.01.038","article-title":"Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway","volume":"36","author":"Marchetti","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.05.063_b0015","unstructured":"Statistics Norway. Births: Statistics Norway,; 2018 [Available from: <https:\/\/www.ssb.no\/en\/befolkning\/statistikker\/fodte> [accessed 17th December 2018]."},{"key":"10.1016\/j.vaccine.2019.05.063_b0020","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/INF.0000000000001656","article-title":"Varicella-related primary health-care visits, hospitalizations and mortality in Norway, 2008\u20132014","author":"Mirinaviciute","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.05.063_b0025","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1186\/s12889-015-1753-y","article-title":"Herpes zoster-associated mortality in Europe: a systematic review","volume":"15","author":"Bricout","year":"2015","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2019.05.063_b0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/003591576505800106","article-title":"The nature of herpes zoster: a long-term study and a new hypothesis","volume":"58","author":"Hope-Simpson","year":"1965","journal-title":"Proc Roy Soc Med"},{"key":"10.1016\/j.vaccine.2019.05.063_b0035","article-title":"Postherpetic neuralgia","volume":"25","author":"Hope-Simpson","year":"1975","journal-title":"J R Coll Gen Pract"},{"key":"10.1016\/j.vaccine.2019.05.063_b0040","unstructured":"Statistics Norway. Health accounts; 2017. Available from: <https:\/\/www.ssb.no\/en\/nasjonalregnskap-og-konjunkturer\/statistikker\/helsesat> [updated 14\/03\/2017]."},{"key":"10.1016\/j.vaccine.2019.05.063_b0045","unstructured":"Varicella and herpes zoster vaccines: WHO position paper, June 2014. Releve epidemiologique hebdomadaire 2014;89(25):265\u201387."},{"key":"10.1016\/j.vaccine.2019.05.063_b0050","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.05.063_b0055","unstructured":"US Food & Drug Administration. Biologics License Application Approval; 2017. Available from: <https:\/\/www.fda.gov\/downloads\/biologicsbloodvaccines\/vaccines\/approvedproducts\/ucm581750.pdf> [accessed 17th December 2018]."},{"key":"10.1016\/j.vaccine.2019.05.063_b0060","unstructured":"European Medicines Agency. Shingrix: Euroean Public Assessment Report; 2018. Available from: <https:\/\/www.ema.europa.eu\/medicines\/human\/EPAR\/shingrix#authorisation-details-section> [accessed 17th December 2018]."},{"key":"10.1016\/j.vaccine.2019.05.063_b0065","unstructured":"Shingles (Herpes Zoster) Vaccination Information for Healthcare Providers cdc.gov: Centers for Disease Control and Prevention; 2017 Available from: <https:\/\/www.cdc.gov\/vaccines\/vpd\/shingles\/hcp\/index.html> [accessed 17th December 2018]."},{"issue":"11","key":"10.1016\/j.vaccine.2019.05.063_b0070","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/INF.0000000000001656","article-title":"Varicella-related primary health-care visits, hospitalizations and mortality in Norway, 2008\u20132014","volume":"36","author":"Mirinaviciute","year":"2017","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.vaccine.2019.05.063_b0075","unstructured":"Norwegian Medicines Agency. Guidelines for the submission of documentation for single technology assessment (STA) of pharmaceuticals; 2018. <https:\/\/legemiddelverket.no\/Documents\/English\/Price%20and%20reimbursement\/Application%20for%20reimbursement\/Guidelines%20151018.pdf> [accessed 17th December 2018]."},{"key":"10.1016\/j.vaccine.2019.05.063_b0080","unstructured":"Norwegian Directorate of Health. [Socioeconomic analyses in the health care sector - a guideline] In Norwegian; 2012. Available from: <https:\/\/helsedirektoratet.no\/retningslinjer\/veileder-i-okonomisk-evaluering-av-helsetiltak> [accessed 17th December 2018]."},{"key":"10.1016\/j.vaccine.2019.05.063_b0085","unstructured":"Statistics Norway. Main economic indicators 2004-2019. Accounts and forecasts. Nasjonalt Regnskap og konjunkturer2016. Available from: <https:\/\/www.ssb.no\/en\/nasjonalregnskap-og-konjunkturer\/artikler-og-publikasjoner\/gradual-upswing-expected-in-2017?tabell=259661> [accessed 17th December 2018]."},{"issue":"1","key":"10.1016\/j.vaccine.2019.05.063_b0090","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12889-015-1514-y","article-title":"The humanistic, economic and societal burden of Herpes Zoster in Europe: a critical review","volume":"15","author":"Gater","year":"2015","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2019.05.063_b0095","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12879-015-0951-7","article-title":"Burden of herpes zoster and post-herpetic neuralgia in Sweden","volume":"15","author":"Nilsson","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2019.05.063_b0100","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5617\/njhe.1792","article-title":"The cost-effectiveness of introducing a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in elderly Danes","volume":"5","author":"Bilde","year":"2016","journal-title":"Nordic J Health Econ"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19307005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19307005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:33:42Z","timestamp":1759401222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19307005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":20,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0264410X19307005"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.063","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Healthcare costs associated with varicella and herpes zoster in Norway","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.05.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}